Exenatide extended-release - Avadel Pharmaceuticals

Drug Profile

Exenatide extended-release - Avadel Pharmaceuticals

Alternative Names: FT 228

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Flamel Technologies
  • Developer Avadel Pharmaceuticals
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 31 Aug 2016 Flamel Technologies completes phase Ib trial for Type 2 diabetes mellitus before August 2016
  • 08 Aug 2016 Efficacy data from a phase Ib trial in Type 2 diabetes mellitus released by Flamel Technologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top